QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation

Código QR

QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation

Triple-negative breast cancer (TNBC) can be further classified into androgen receptor (AR)-positive TNBC and AR-negative TNBC or quadruple-negative breast cancer (QNBC). Here, we investigated genomic instability in 53 clinical cases by array-CGH and miRNA expression profiling. Immunohistochemical an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shristi Bhattarai, Bruna M. Sugita, Stefanne M. Bortoletto, Aline S. Fonseca, Luciane R. Cavalli, Ritu Aneja
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	triple-negative breast cancer quadruple-negative breast cancer AR loss genomic instability copy number array-CGH Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/f71df66240004edba2369d048b0f563a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Resultados del tratamiento del cáncer de mama, Programa Nacional de Cáncer del Adulto
por: Castillo,César del SM., et al.
Publicado: (2017)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

Tumor suppressive function of Matrin 3 in the basal-like breast cancer
por: Yang,Jaehyuk, et al.
Publicado: (2020)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases
por: Seung-Uon Shin, et al.
Publicado: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Effect of statins on breast cancer recurrence and mortality: a review
por: Van Wyhe RD, et al.
Publicado: (2017)

An Update on the Molecular Pathology of Metaplastic Breast Cancer
por: McCart Reed AE, et al.
Publicado: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Alyssa Vito, et al.
Publicado: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Repurposing hyperpolarization‐activated cyclic nucleotide‐gated channels as a novel therapy for breast cancer
por: Ka‐Chun Mok, et al.
Publicado: (2021)

Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer
por: Li X, et al.
Publicado: (2020)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Miyuki Kitahara, et al.
Publicado: (2021)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: Luis de la Cruz-Merino, et al.
Publicado: (2021)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
por: Ilie SM, et al.
Publicado: (2018)

Terminal Cyclohexane-Type Meroterpenoids from the Fruiting Bodies of Ganoderma cochlear
por: Fu-Ying Qin, et al.
Publicado: (2021)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Mirjana Prvanović, et al.
Publicado: (2021)

miR-29b-3p promotes progression of MDA-mB-231 triple-negative breast cancer cells through downregulating TRAF3
por: Zhang,Bao, et al.
Publicado: (2019)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Yubao Zhang, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
por: Cook MT, et al.
Publicado: (2016)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles
por: Huang J, et al.
Publicado: (2021)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
por: Wang X, et al.
Publicado: (2021)

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
por: Amna Ameer, et al.
Publicado: (2021)

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
por: Veronica Vella, et al.
Publicado: (2021)

Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
por: Saliha Karagöz Eren, et al.
Publicado: (2021)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
por: Jin X, et al.
Publicado: (2020)

Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer
por: Zheng H, et al.
Publicado: (2016)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)